ATXI
Avenue Therapeutics
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 180.17M; Volume: 12.21K; AvgVol 3m: 41.37K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.97; EPS growth quarter/prev quarter: 73.20%;
EPS growth this year: 21.70%; EPS growth past 5 years: ;
EPS ttm: -0.66;
P/S: ; P/B: 43.04; P/Cashflow: ; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -123.90%; ROE – return on equity: -150.70%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.60%; Insider Transactions:-1.41%;
Institutional Ownership: 16.30%; Institutional Transactions: 34.13%;
Data update: 07/10/2020.